Nicolas R Smoll1, Brett Hamilton1. 1. Department of Medicine, Peninsula Health, Frankston, Victoria, Australia (N.R.S., B.H.).
Abstract
BACKGROUND: The purpose of this study was to investigate the relationship between age and the incidence and relative survival of anaplastic astrocytoma (AA). METHODS: Data from the Surveillance, Epidemiology and End Results database were used to identify 3202 patients with AA. These data were analyzed to assess incidence rates, relative survival, and the standardized mortality ratio across age groups. Time trends were modeled using delayed-entry modeling. RESULTS: The overall incidence of AA was an age-adjusted rate of 3.5 per million person/years. The overall age-standardized 5- and 10-year relative survival rates of populations with AA were 23.6% and 15.1%, respectively. The overall standardized mortality ratio for the entire cohort was 46 (95% confidence interval: 45, 48). CONCLUSIONS: Patients with a diagnosis of AA are 46 times more likely to die than persons matched for age/sex/year of the general population. The effect of age on survival is present for only the first 2 years postdiagnosis. Measuring the effect of age on survival for populations with an AA is not amenable to using models with proportional hazards as an assumption because of the presence of a reverse fork-type interaction.
BACKGROUND: The purpose of this study was to investigate the relationship between age and the incidence and relative survival of anaplastic astrocytoma (AA). METHODS: Data from the Surveillance, Epidemiology and End Results database were used to identify 3202 patients with AA. These data were analyzed to assess incidence rates, relative survival, and the standardized mortality ratio across age groups. Time trends were modeled using delayed-entry modeling. RESULTS: The overall incidence of AA was an age-adjusted rate of 3.5 per million person/years. The overall age-standardized 5- and 10-year relative survival rates of populations with AA were 23.6% and 15.1%, respectively. The overall standardized mortality ratio for the entire cohort was 46 (95% confidence interval: 45, 48). CONCLUSIONS:Patients with a diagnosis of AA are 46 times more likely to die than persons matched for age/sex/year of the general population. The effect of age on survival is present for only the first 2 years postdiagnosis. Measuring the effect of age on survival for populations with an AA is not amenable to using models with proportional hazards as an assumption because of the presence of a reverse fork-type interaction.
Authors: M P W A Houben; K K H Aben; J L J M Teepen; A Y N Schouten-Van Meeteren; C C Tijssen; C M Van Duijn; J W W Coebergh Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Johan M Kros; Thierry Gorlia; Mathilde C Kouwenhoven; Ping-Pin Zheng; V Peter Collins; Dominique Figarella-Branger; Felice Giangaspero; Caterina Giannini; Karima Mokhtari; Sverre J Mørk; Anders Paetau; Guido Reifenberger; Martin J van den Bent Journal: J Neuropathol Exp Neurol Date: 2007-06 Impact factor: 3.685
Authors: Jonas Nilsson; Georg Holgersson; Tobias Carlsson; Roger Henriksson; Stefan Bergström; Michael Bergqvist Journal: Oncol Lett Date: 2017-02-23 Impact factor: 2.967
Authors: Alexandra Rizzitelli; Nicolas R Smoll; Michael P Chae; Warren M Rozen; David J Hunter-Smith Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: Josie Hayes; Helene Thygesen; Alastair Droop; Thomas A Hughes; David Westhead; Sean E Lawler; Heiko Wurdak; Susan C Short Journal: Oncoscience Date: 2014-12-26
Authors: Bawarjan Schatlo; Javier Fandino; Nicolas R Smoll; Oliver Wetzel; Luca Remonda; Serge Marbacher; Wolfgang Perrig; Hans Landolt; Ali-Reza Fathi Journal: Neuro Oncol Date: 2015-04-08 Impact factor: 12.300
Authors: Robert F Koncar; Zhengtao Chu; Lindsey E Romick-Rosendale; Susanne I Wells; Timothy A Chan; Xiaoyang Qi; El Mustapha Bahassi Journal: Oncotarget Date: 2017-02-28